BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu Z, Man S, Sun R, Li Z, Wu Y, Zuo D. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer. International Immunopharmacology 2020;85:106613. [DOI: 10.1016/j.intimp.2020.106613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Cheng D, Wang L, Qu F, Yu J, Tang Z, Liu X. Identification and construction of a 13-gene risk model for prognosis prediction in hepatocellular carcinoma patients. J Clin Lab Anal 2022;:e24377. [PMID: 35421268 DOI: 10.1002/jcla.24377] [Reference Citation Analysis]
2 Massafra M, Passalacqua MI, Gebbia V, Macrì P, Lazzari C, Gregorc V, Buda C, Altavilla G, Santarpia M. Immunotherapeutic Advances for NSCLC. Biologics 2021;15:399-417. [PMID: 34675481 DOI: 10.2147/BTT.S295406] [Reference Citation Analysis]
3 Ghaemi A, Bagheri E, Abnous K, Taghdisi SM, Ramezani M, Alibolandi M. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy. Life Sci 2021;267:118969. [PMID: 33385410 DOI: 10.1016/j.lfs.2020.118969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Maharjan R, Subedi L, Pangeni R, Jha SK, Kang SH, Chang KY, Byun Y, Choi JU, Park JW. Metronomic delivery of orally available pemetrexed-incorporated colloidal dispersions for boosting tumor-specific immunity. Drug Deliv 2021;28:2313-28. [PMID: 34730056 DOI: 10.1080/10717544.2021.1995077] [Reference Citation Analysis]
5 da Costa V, van Vliet SJ, Carasi P, Frigerio S, García PA, Croci DO, Festari MF, Costa M, Landeira M, Rodríguez-Zraquia SA, Cagnoni AJ, Cutine AM, Rabinovich GA, Osinaga E, Mariño KV, Freire T. The Tn antigen promotes lung tumor growth by fostering immunosuppression and angiogenesis via interaction with Macrophage Galactose-type lectin 2 (MGL2). Cancer Lett 2021;518:72-81. [PMID: 34144098 DOI: 10.1016/j.canlet.2021.06.012] [Reference Citation Analysis]
6 Kumar S, Sarthi P, Mani I, Ashraf MU, Kang MH, Kumar V, Bae YS. Epitranscriptomic Approach: To Improve the Efficacy of ICB Therapy by Co-Targeting Intracellular Checkpoint CISH. Cells 2021;10:2250. [PMID: 34571899 DOI: 10.3390/cells10092250] [Reference Citation Analysis]
7 Shen L, Fu H, Tao G, Liu X, Yuan Z, Ye X. Pre-Immunotherapy Contrast-Enhanced CT Texture-Based Classification: A Useful Approach to Non-Small Cell Lung Cancer Immunotherapy Efficacy Prediction. Front Oncol 2021;11:591106. [PMID: 33968716 DOI: 10.3389/fonc.2021.591106] [Reference Citation Analysis]
8 Ando K, Manabe R, Kishino Y, Kusumoto S, Yamaoka T, Tanaka A, Ohmori T, Ohnishi T, Sagara H. Comparative Efficacy and Safety of Anti-PD-1/PD-L1 Immune Checkpoint Inhibitors for Refractory or Relapsed Advanced Non-Small-Cell Lung Cancer-A Systematic Review and Network Meta-Analysis. Cancers (Basel) 2020;13:52. [PMID: 33561074 DOI: 10.3390/cancers13010052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Li Y, Yu X, Wang Y, Zheng X, Chu Q. Kaempferol-3-O-rutinoside, a flavone derived from Tetrastigma hemsleyanum, suppresses lung adenocarcinoma via the calcium signaling pathway. Food Funct 2021. [PMID: 34338262 DOI: 10.1039/d1fo00581b] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Fiorica F, Belluomini L, Giuliani J, Urbini B, Milella M, Frassoldati A, Pilotto S, Giorgi C. Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report. Immunotherapy 2021;13:971-6. [PMID: 34180714 DOI: 10.2217/imt-2021-0039] [Reference Citation Analysis]
11 Ilié M, Hofman V, Bontoux C, Heeke S, Lespinet-fabre V, Bordone O, Lassalle S, Lalvée S, Tanga V, Allegra M, Salah M, Bohly D, Benzaquen J, Marquette C, Long-mira E, Hofman P. Setting Up an Ultra-Fast Next-Generation Sequencing Approach as Reflex Testing at Diagnosis of Non-Squamous Non-Small Cell Lung Cancer; Experience of a Single Center (LPCE, Nice, France). Cancers 2022;14:2258. [DOI: 10.3390/cancers14092258] [Reference Citation Analysis]
12 Bossageon M, Swalduz A, Chouaïd C, Bylicki O. First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data. BioDrugs 2022. [PMID: 35147894 DOI: 10.1007/s40259-022-00515-z] [Reference Citation Analysis]
13 Setordzi P, Chang X, Liu Z, Wu Y, Zuo D. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy. Eur J Pharmacol 2021;895:173867. [PMID: 33460617 DOI: 10.1016/j.ejphar.2021.173867] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Ozawa Y, Hicks KC, Minnar CM, Knudson KM, Schlom J, Gameiro SR. Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa. Oncoimmunology 2021;10:1915561. [PMID: 33996267 DOI: 10.1080/2162402X.2021.1915561] [Reference Citation Analysis]